ArticleInternational journal of rheumatology2009
Controversies on rituximab therapy in sjögren syndrome-associated lymphoproliferation.
Article in International journal of rheumatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 38 citations in OpenAlex.
- Emerging treatment for Sjögren's disease: a review of recent phase II and III trials.Expert opinion on emerging drugs · 2023Review
- A systematic review and meta-analysis of thymic mucosa-associated lymphoid tissue lymphoma.Journal of thoracic disease · 2022Article
- A comparison of rituximab with cyclophosphamide in terms of efficacy and complications as induction therapy for treating granulomatosis with polyangiitis: A three-center study.European journal of rheumatology · 2022Article
- Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome.Annals of the rheumatic diseases · 2019Article
- Biologic therapy for refractory scleritis: a new treatment perspective.International ophthalmology · 2015Review
- Sjögren's syndrome complicated with retroperitoneal Non-Hodgkin's lymphoma: A case of an elderly woman during methotrexate treatment, treated with R-CHOP.European journal of rheumatology · 2014Article
- Possible Mechanisms of Lymphoma Development in Sjögren's Syndrome.Current immunology reviews · 2013Article
- Rituximab treatment for Sjogren syndrome-associated non-Hodgkin's lymphoma: case series.Rheumatology international · 2012Article
- Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.Nature reviews. Rheumatology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sjögren's syndrome (SS) is a systemic autoimmune disease characterized by chronic inflammation of salivary and lachrymal glands, and frequently accompanied by systemic symptoms. A subgroup of SS patients develops malignant B cell non-Hodgkin's lymphoma (NHL), usually of the mucosa-associated lymphoid tissue (MALT) type and very often located in the major salivary glands. Currently, there is a lack of evidence-based intervention therapy which may influence SS-related chronic inflammation and lymphoproliferation. B cells are involved in the pathogenesis of SS, and B cell downregulation may lead to a decrease of disease activity. Rituximab (RTX), a chimeric monoclonal antibody targeting the CD20 antigen on the B cell surface, has been successfully investigated in other autoimmune diseases, such as rheumatoid arthritis, systemic lupus erythematosus, ANCA-associated vasculitis, and mixed cryoglobulinemic syndrome. Preliminary experiences of RTX therapy in SS patients with or without a lymphoproliferative disorder suggest that SS patients with more residual exocrine gland function might better benefit from RTX. Efficacy of RTX in SS-associated B-cell lymphoma, mainly in low-grade salivary gland lymphomas, remains an open issue.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.